[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641262":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":36,"responsibleParty":43,"collaborators":45,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":18,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":18,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"China Medical University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CKD-1 plus standard therapy","EXPERIMENTAL","Participants receive CKD-1 (13.5 g\u002Fday) orally in addition to standard care for 12 weeks. Standard care includes guideline-based management of blood pressure and kidney protection therapy, which remains stable during the study period.",[13],"Other: Chinese herbal formula CKD-1",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard therapy alone","NO_INTERVENTION","Participants receive standard care alone for 12 weeks. Standard care includes guideline-based management of blood pressure and kidney protection therapy, maintained without addition of Chinese herbal medicine during the study period.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Chinese herbal formula CKD-1","CKD-1 is a traditional Chinese herbal formula administered orally at a total daily dose of 13.5 g for 12 weeks. The formula consists of Astragalus membranaceus (3.0 g), Salvia miltiorrhiza (2.5 g), Poria cocos (2.0 g), Moutan cortex (1.5 g), Scutellaria baicalensis (1.5 g), Lonicera japonica (1.5 g), and Alisma orientale (1.5 g). It is used as an adjunct to standard care in patients with stage 3-4 non-diabetic chronic kidney disease.",[9],[25],{"name":26,"affiliation":27,"role":28},"Ing-Shiow Lai, MD, PhD","China Medical University Beigang Hospital","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"CHE-JU CHANG, MD","CONTACT","+886-5-7837901","1229","160076@tool.caaumed.org.tw",[37],{"facility":27,"status":18,"city":38,"state":39,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":18,"geoPoint":18,"contacts":41},"Yunlin","Taiwan","TW",[42],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[46],{"name":27,"class":6},"100641262","effect-of-chinese-herbal-medicine-on-kidney-function-in-non-diabetic-ckd-100641262",false,"NCT07657338","Effect of Chinese Herbal Medicine on Kidney Function in Non-Diabetic CKD","Effects of Chinese Herbal Medicine as an Adjunctive Therapy on Renal Function in Patients With Non-Diabetic Chronic Kidney Disease: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Patients diagnosed with stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes N18.3-N18.4.\n* Ability to understand the study procedures and provide written informed consent.\n* Willingness to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment.\n* Participation in another clinical trial within 3 months that may affect renal function.\n* Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.\n* Pregnancy or breastfeeding.\n* History of diabetes mellitus.\n* Malignancy currently receiving chemotherapy, radiotherapy, or other systemic anticancer treatment.\n* End-stage disease defined under palliative care regulations.\n* Known allergy to any components of the CKD-1 herbal formula, including Astragalus membranaceus, Salvia miltiorrhiza, Poria cocos, Moutan cortex, Scutellaria baicalensis, Lonicera japonica, or Alisma orientale.","ALL","18 Years",{"count":57,"type":58},66,"ESTIMATED","INTERVENTIONAL",[61],"NA","This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (CKD-1) as an add-on therapy to standard treatment in patients with stage 3-4 non-diabetic chronic kidney disease. Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with CKD-1 for 12 weeks. Kidney function, urine protein levels, and quality of life will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether CKD-1 can improve renal function and quality of life in this patient population.",[64],"Non-diabetic Chronic Kidney Disease",[66,67,68,69],"Traditional Chinese Medicine","non diabetic chronic kidney disease","Adjunctive Therapy","Pilot Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-15",{"date":73,"type":74},"2026-06-18","ACTUAL",{"date":76,"type":58},"2026-06-11",{"date":78,"type":58},"2026-12-31",{"name":5,"class":6},1]